Abstract
Previously we have described the induction of MHC-unrestricted killer cells against bladder tumour cells by bacillus Calmette-Guérin (BCG), termed BCG-activated killer (BAK) cells. In the present paper we deal with the accessory-cell requirement for the activation of BAK cells. We show that monocytes are required for activating BAK cells, since no cytotoxicity can be induced in the absence of monocytes. Therefore, these phagocytes may represent the first step during the activation cascade of BAK cells. Furthermore, the presence of CD4+ T cells was essential for generating BAK cells: depleting peripheral blood mononuclear cells of CD4− cells prior to stimulation with BCG abolished the cytotoxicity against bladder tumour cells. Experiments with monoclonal antibodies (mAb) neutralizing the activity of either interleukin-2 (IL-2) or interferon γ (IFNγ) underlined the importance of these cytokines: both mAb blocked the induction of BAK cells. Since both cytokines are related to the so-called Th1 pattern of T cells, we consider the second step of the generation of BAK cells as follows: monocytes presenting antigens of BCG trigger Th1-like cells in a preferred manner. These Th1-like T cells secrete IL-2 and IFNγ and, thus, activate the BAK effector cells. Since CD4+ cells are dominant in the cells infiltrating the bladder wall after intravesical instillation of BCG in vivo, we postulate an important role for the Th1 subpopulation. We further postulate that the occurrence of macrophages in this infiltrate seems to be significant in the maintenance of the relapse-free state of the patient.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Boer EC de, Jong WH de, Steerenberg PA, Aarden LA, Tetteroo E, Groot ER de, Meijden APM van der, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ (1992) Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical immunotherapy with bacillus Calmette-Guerin in superficial bladder cancer. Cancer Immunol Immunother 34:306
Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad H-D (1990) Effects of local BCG therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144:53
Böhle A, Nowe CH, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad H-D (1990) Elevations of cytokines interleukin-1, interleukin-2, and tumor necrosis factor in the urine of patients following intravesical BCG immunotherapy. J Urol 144:59
Böhle A, Thanhäuser A, Ulmer AJ, Ernst M, Flad H-D, Jocham D (1993) Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in-vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon. J Urol 150:1932
Bosch J van der, Rüller S, Horn D, Schumann R, Schlaak M (1990) Density-dependent tumor cell death and reversible cell cycle arrest: mutually exclusive modes of monocyte-mediated growth control. Exp Cell Res 187:185
Böyum A (1968) Isolation of mononuclear cells and granulocytes from human blood. Scand J Lab Clin Invest 21:77
Chapman PB, Houghton AN (1993) Non-antibody immunotherapy of cancer. Curr Opin Immunol 5:726
Cher DJ, Mosmann TR (1985) Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by Th1 clones. J Immunol 138:3688
Ennen J, Ernst M, Flad H-D (1989) The effect of interleukin 2 on Fe-gamma receptor function of human monocytes requires specific intercellular interaction. Immunobiology 179:17
Ernst M, Lange A, Flad H-D, Havel A, Ennen J, Ulmer AJ (1984) Dissociation of responses measured by natural cytotoxicity and chemiluminescence. Eur J Immunol 14:634
Grage-Griebenow E, Lorenzen D, Fetting R, Flad H-D, Ernst M (1993) Phenotypical and functional characterization of FCτ receptor I (CD64)-negative monocytes, a minor human monocyte subpopulation with high acessory and antiviral activity. Eur J Immunol 23:3126
Jackson AM, Prescott S, Hawkyard SJ, James K, Chisholm GD (1993) The immunomodulatory effects of urine from patients with superficial bladder cancer receiving intravesical Evans BCG therapy. Cancer Immunol Immunother 36:25
Julius MH, Simpson E, Herzenberg LA (1973) A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol 3:645
Phillips JH, Lanier LL (1986) Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164:814
Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1990) Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144:1248
Ratliff TL, Gillen D, Catalona WJ (1987) Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 137:155
Ratliff TL, Palmer JO, McGarr JA, Brown EJ (1987) Intravesical BCG therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of BCG. Cancer Res 47:1762
Ratliff TL, Hudson MA, Catalona WJ (1991) Strategy for improving therapy of superficial bladder cancer. World J Urol 9:95
Ratliff TL, Ritchey JK, Yuan JJJ, Andriole GL, Catalona WJ (1993) T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150:1018
Rieneck K, Diamant M, Haahr P-M, Schönharting M, Bendtzen K (1993) In vitro immunomodulatory effects of pentoxifylline. Immunol Lett 37:131
Rosenberg SA (1985) Lymphokine activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst 75:595
Rott O, Cash E, Fleischer B (1993) Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1-but not type 2-associated lymphokine production, prevents induction of autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 23:1745
Schur PH, Chang D-M, Baptiste P, Uhteg LC, Hanson DC (1990) Human monocytes produce IL-1 and an inhibitor of IL-1 in response to different signals. Clin Immunol Immunopathol 57:45
Thanhäuser A, Böhle A, Flad H-D, Ernst M, Mattern T, Ulmer AJ (1993) Induction of bacillus-Calmette-Guérin-activated killer cells from human peripheral blood mononuclear cell against human bladder carcinoma cells lines in vitro. Cancer Immunol Immunother 37:105
Thanhäuser A, Reiling N, Böhle A, Toellner K-M, Duchrow M, Scheel D, Schlüter C, Ernst M, Flad H-D, Ulmer AJ (1993) Pentoxifylline: a potent inhibitor of IL-2 and IFN-gamma biosynthesis and BCG-induced cytotoxicity. Immunology 80:151
Tilg H, Eibl B, Pichl M, Gächter A, Herold M, Branova J, Huber C, Niederwieser D (1993) Immune response modulation by pentoxifylline in vitro. Transplantation 56:196
Wang M-H, Flad H-D, Böhle A, Chen Y-Q, Ulmer AJ (1991) Cellular cytotoxicity of human natural killer cells and lymphokine-activated killer cells against bladder carcinoma cell lines. Immunol Lett 27:191
Wang M-H, Chen Y-Q, Schlüter C, Arnoldi J, Gercken J, Ernst M, Gerdes J, Flad H-D, Böhle A, Ulmer AJ (1993) Specific activation of human peripheral blood gamma/delta+ T lymphocytes by sonicated antigens ofMycobacterium tuberculosis: role in vitro in killing human bladder carcinoma cells lines. Scand J Immunol 38:239
Zabel P, Leimenstoll G, Schröder P, Elfeldt R, Schlaak M, Niedermayer W (1991) Pentoxifylline suppresses OKT3-induced tumor necrosis factor alpha formation in renal transplant recipients. Z Tx Med 3:62
Zabel P, Wolter DT, Schönharting MM, Schade U (1989) Oxpentifylline in endotoxaemia. Lancet 23/30:1474
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Thanhäuser, A., Böhle, A., Schneider, B. et al. The induction of bacillus-Calmette-Guérin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 40, 103–108 (1995). https://doi.org/10.1007/BF01520291
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01520291